CERo Therapeutics went public via a SPAC merger with Phoenix Biotech in a $50m deal.

CERo Therapeutics, an innovative immunotherapy company, went via a SPAC merger with Phoenix Biotech, a blank-check company, in a $50m deal. “We are thrilled to join forces with PBAX. With CERo technology we see an opportunity to engage the body’s full immune repertoire for optimized cellular immunotherapy. Chris and Brian bring a wealth of experience to the CERo team during this important time as we look to test the first CER T cell therapeutic candidate in the clinic," Daniel Corey, CERo CEO.